<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><link rel="stylesheet" href="/css/isb.css" /><title>ProteomeXchange Dataset PXD011803</title>
</head><body bgcolor="#f4f6f8" marginwidth="0" marginheight="0">	<table width="100%" height="127" background="/images/topbackground.jpg" style="box-shadow: 0 6px 8px 0 rgba(0,0,0,0.3);">	<tr align="center"><td><a href="http://www.proteomexchange.org/" border="0"><img src="/images/proteomexchange.png"></a></td><td><a href="http://proteomecentral.proteomexchange.org/" border="0"><img src="/images/proteomecentral.png"></a></td></tr>	</table>		<!-- Main content area here --><!-- BEGIN main content -->

	 <link rel='stylesheet' id='style-css'  href='../javascript/css/patchwork.css' type='text/css' media='all' />
         <script type="text/javascript" src="/javascript/js/toggle.js"></script>
      
       <div id="main">
       <a class="linkback" href="http://proteomecentral.proteomexchange.org/cgi/GetDataset"> &lt;&lt;&lt; Full experiment listing </a>
       <div id="dataset-primary" class="site-content">
       <h1 class="dataset-title">PXD011803</h1>
    
	<div class="dataset-content">
	PXD011803 is an <b>original dataset</b> announced via ProteomeXchange.<BR><BR><div class='dataset-secthead'>Dataset Summary</div>
<table class='dataset-summary'><tr><td><b>Title</b></td><td>Combined FGFR and Akt pathway inhibition abrogate growth of EGFR TKI-resistant NSCLC cells with upregulated FGFR1 expression</td></tr><tr><td><b>Description</b></td><td class='breakwords'>Introduction: The clinical benefit of EGFR tyrosine kinase inhibitor (TKI) treatment in non-small cell lung cancer (NSCLC) patients with activating EGFR mutations is temporary, as virtually all patients develop acquired EGFR TKI resistance that occurs via diverse mechanisms. Here, we identified increased FGFR1 expression as such a resistance mechanism and using pathways analysis and drug combination testing we identified a novel combination treatment to control growth of these resistant tumors.  Methods: Novel erlotinib-resistant NSCLC cell lines were generated and analyzed by mass spectrometry-based proteomics to identify altered pathways associated with erlotinib resistance. The altered pathways were further analyzed in gefitinib and osibenib resistant cell lines. Small molecule inhibitor combinations were used to block the altered pathways and investigate growth reduction in vitro and in two xenograft mouse models. FGFR1 mRNA levels were examined in pre- and (post?)- EGFR TKI treatment clinical tumor samples. Results: Proteomic analysis revealed increased expression of FGFR1 and AXL as well as increased Akt and ERK1/2 activation in a panel of novel erlotinib-resistant HCC827 cell lines. Combined treatment with erlotinib or osimertinib and a panel of small molecule inhibitors targeting AXL/MET, FGFRs, Akt, PI3K/mTOR, MEK or ERK1/2 showed that the most prominent re-sensitization to EGFR TKI occurred with the pan-FGFR inhibitor, PD173074. Interestingly, simultaneous blockade of components of the Akt pathway using specific Akt or dual PI3K-mTOR inhibitors combined with inhibitors targeting the FGFR family exhibited the most efficient growth inhibition of FGFR1 overexpressing EGFR TKI-resistant cell lines. Phosphorylation of proteins downstream of Akt, including PRAS40, FOXO and S6 ribosomal protein, were completely abrogated by PD173074 combined with the Akt inhibitor GSK2141795 . Combination treatment with PD173074 and an Akt inhibitor exhibited synergistic growth inhibition in vivo in two FGFR1 overexpressing NSCLC EGFR TKI-resistant animal models.  Conclusion: The significant growth inhibition in vitro and in vivo observed with PD173074 combined with Akt compared to either drug alone imply that inhibition of several key targets may be beneficial in controlling erlotinib-resistant NSCLC. The complete abrogation of PRAS40, FOXO and S6 phosphorylations by PD173074 combined with an Akt inhibitor indicates that the Akt pathway is no longer active.</td></tr><tr><td><b>HostingRepository</b></td><td>PRIDE</td></tr><tr><td><b>AnnounceDate</b></td><td>2021-07-08</td></tr>
                <tr><td><b>AnnouncementXML</b></td><td><a href='GetDataset?ID=PXD011803.0-1&outputMode=XML&test=no' target="_blank">Submission_2021-07-08_05:47:53.189.xml</a></td></tr>
                <tr><td><b>DigitalObjectIdentifier</b></td><td><a href="" target="_blank"></a></td></tr><tr><td><b>ReviewLevel</b></td><td>Peer-reviewed dataset</td></tr><tr><td><b>DatasetOrigin</b></td><td>Original dataset</td></tr><tr><td><b>RepositorySupport</b></td><td>Unsupported dataset by repository</td></tr><tr><td><b>PrimarySubmitter</b></td><td>Hans Christian Beck</td></tr><tr><td><b>SpeciesList</b></td><td> scientific name: Homo sapiens (Human);  NCBI TaxID: 9606; </td></tr><tr><td><b>ModificationList</b></td><td>monohydroxylated residue; iodoacetamide derivatized residue; deamidated residue</td></tr><tr><td><b>Instrument</b></td><td>Q Exactive</td></tr></table>
<div class='dataset-secthead'>Dataset History</div>
<table class="dataset-summary">
<tr><th>Revision</th><th>Datetime</th><th>Status</th><th>ChangeLog Entry</th></tr>
<tr><td >0</td><td >2018-11-23 00:35:31</td><td >ID requested</td><td ></td></tr>
<tr><td class="dataset-currentrev"><a href="GetDataset?ID=PXD011803-1&test=no"><span class='current'>&#9205;</span> 1</a></td><td class="dataset-currentrev">2021-07-08 05:47:53</td><td class="dataset-currentrev">announced</td><td class="dataset-currentrev"></td></tr>
</table>
<div class='dataset-secthead'>Publication List </div>
<table class='dataset-summary'>
<tr><td>Dataset with its publication pending</td></tr></table>
<div class='dataset-secthead'>Keyword List </div>
<table class='dataset-summary'>
<tr><td>ProteomeXchange project tag: Cancer (B/D-HPP), Biology/Disease-Driven Human Proteome Project (B/D-HPP), Human Proteome Project</td></tr><tr><td>curator keyword: Biomedical</td></tr><tr><td>submitter keyword: shutgun proteomics 4-plex itraq, AKT inhibitors</td></tr></table>
<div class='dataset-secthead'>Contact List </div>
<table class='dataset-summary'>
<tr><th colspan='2'>Hans C Beck</th></tr>
<tr><td>contact affiliation</td><td>Centre for Clinical Proteomics, Odense University Hospital, Sdr Boulevard 29, DK-5000 Odense C</td></tr><tr><td>contact email</td><td>hans.christian.beck@rsyd.dk</td></tr><tr><td>lab head</td><td></td></tr><tr><th colspan='2'>Hans Christian Beck</th></tr>
<tr><td>contact affiliation</td><td>Odense University Hospital, Odense, Denmark</td></tr><tr><td>contact email</td><td>hans.christian.beck@rsyd.dk</td></tr><tr><td>dataset submitter</td><td></td></tr></table>
<div class='dataset-secthead'>Full Dataset Link List </div>
<table class='dataset-summary'>
<tr><td><a href=ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD011803 target="_blank">Dataset FTP location</a></td></tr><tr><td><a href=http://www.ebi.ac.uk/pride/archive/projects/PXD011803 target="_blank">PRIDE project URI</a></td></tr></table>

		 <div class='dataset-secthead'>Repository Record List </div>
                 <div id="less" onclick='toggle("less","more","repositoryRecordList")' title='Expand Record List'>[ + ]</div>
		 <div id="more" onclick='toggle("more","less","repositoryRecordList")' title='Hide Record List' style='display: none'>[ - ]</div>
		 <ul id="repositoryRecordList" style='display: none'>
        <li>PRIDE<ol><li><a href="http://www.ebi.ac.uk/pride/archive/projects/PXD011803" target="_blank">PXD011803</a><ol><li>Label: PRIDE project</li><li>Name: Combined FGFR and Akt pathway inhibition abrogate growth of EGFR TKI-resistant NSCLC cells with upregulated FGFR1 expression</li></ol></li></li></ul>

      
	 </div><!-- #content -->
	 </div><!-- #primary .site-content -->
	 </div><!-- #main -->
      <!-- END main content -->	<!-- Begin Footer -->	<br clear="all">	<div class="footer">	<table width="100%"><tr>	<td style="vertical-align:top; text-align:left; padding: 10px;">If you have a question or comment about ProteomeXchange, please <a href="http://www.proteomexchange.org/contact">contact us</a>!<BR>	<a href="http://www.proteomexchange.org/subscribe/index.html"><img width="70" height="20" src="/images/subscribe_button-small.jpg"><font size="+1" color="#aa0000"> to receive all new ProteomeXchange dataset release announcements!</font></a>	</td>	<td style="text-align:right; padding: 10px;">	<a class="logolink" target="_blank" href="http://www.ebi.ac.uk/"><img src="/images/ebi_footer_logo.png"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://www.isbscience.org/"><img src="/images/isb.jpg"></a>&nbsp;&nbsp;&nbsp;&nbsp;	<a class="logolink" target="_blank" href="http://ec.europa.eu/research/fp7/index_en.cfm"><img src="/images/capacities.png"></a>	</td></tr></table>	</div>				</body></html>